Activins and activin antagonists in the prostate and prostate cancer

Molecular and Cellular Endocrinology

Volumn 359, Issue 1-2, 2012, Pages 107-112

  Gold, Elspeth ^a   Risbridger, Gail ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Activin; Cancer; Follistatin prostate; Inhibin

Indexed keywords

ACTIVIN; ACTIVIN A; ACTIVIN BETAC; BONE MORPHOGENETIC PROTEIN AND ACTIVIN MEMBRANE BOUND INHIBITOR; FOLLISTATIN; FOLLISTATIN RELATED PROTEIN; INHIBIN; INHIBIN ALPHA; MESSENGER RNA; PROTEIN CRIPTO; UNCLASSIFIED DRUG;

BINDING AFFINITY; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; GROWTH INHIBITION; HORMONE RELEASE; HUMAN; IMMUNOREACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; UPREGULATION;

ACTIVINS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FOLLISTATIN; FOLLISTATIN-RELATED PROTEINS; GPI-LINKED PROTEINS; HUMANS; INHIBINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84861656630     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.07.005     Document Type: Review

References (55)

1. Balanathan P., Ball E.M.A., et al. Epigenetic regulation of inhibin a-subunit gene in prostate cancer cell lines. J. Mol. Endocrinol. 2004, 32(1):55-67.
2. Balanathan P., Williams E.D., et al. Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. Br. J. Cancer 2009, 100(11):1784-1793.
3. Ball E.M., Mellor S.L., et al. Cancer progression: is inhibin alpha from Venus or Mars?. Cytokine Growth Factor Rev. 2004, 15(5):291-296.
4. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6(7):506-520.
5. Burger H.G., Robertson D.M., et al. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Clin. Endocrinol. (Oxf) 1996, 44(4):413-418.
6. Chen Y.G., Lui H.M., et al. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp. Biol. Med. (Maywood) 2002, 227(2):75-87.
7. de Kretser D.M., Robertson D.M. The isolation and physiology of inhibin and related proteins. Biol. Reprod. 1989, 40(1):33-47.
8. de Kretser D.M., Hedger M.P., Loveland K.L., Phillips D.J. Inhibins, activins and follistatin in reproduction. Hum. Reprod. Update 2002, 8(6):529-541.
9. de Kretser D.M., Meinhardt A., et al. The roles of inhibin and related peptides in gonadal function. Mol. Cell. Endocrinol. 2000, 161(1-2):43-46.
10. Fang J., Wang S.Q., et al. Genes coding for mouse activin beta C and beta E are closely linked and exhibit a liver-specific expression pattern in adult tissues. Biochem. Biophys. Res. Commun. 1997, 231(3):655-661.
11. Fang J., Yin W., et al. Molecular cloning of the mouse activin beta E subunit gene. Biochem. Biophys. Res. Commun. 1996, 228(3):669-674.
12. Fulda S. Tumor resistance to apoptosis. Int. J. Cancer 2009, 124(3):511-515.
13. Gold E., Jetly N., et al. Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo. Am. J. Pathol. 2009, 174(1):184-195.
14. Gold E.J., O'Bryan M.K., et al. Cell-specific expression of betaC-activin in the rat reproductive tract, adrenal and liver. Mol. Cell. Endocrinol. 2004, 222(1-2):61-69.
15. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
16. Harrison C.A., Gray P.C., Vale W.W., Robertson D.M. Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol. Metab. 2005, 16(2):73-78.
17. Hashimoto O., Nakamura T., et al. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. J. Biol. Chem. 1997, 272(21):13835-13842.
18. Illingworth P.J., Groome N.P., et al. Inhibin-B: a likely candidate for the physiologically important form of inhibin in men. J. Clin. Endocrinol. Metab. 1996, 81(4):1321-1325.
19. Kingsley D.M. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 1994, 8(2):133-146.
20. Lau A.L., Kumar T.R., et al. Activin betaC and betaE genes are not essential for mouse liver growth, differentiation, and regeneration. Mol. Cell. Biol. 2000, 20(16):6127-6137.
21. Lau A.L., Nishimori K., et al. Structural analysis of the mouse activin beta C gene. Biochim. Biophys. Acta 1996, 1307(2):145-148.
22. Ling N., Ying S.Y., et al. Isolation and partial characterization of a Mr 32, 000 protein with inhibin activity from porcine follicular fluid. Proc. Natl. Acad. Sci. USA 1985, 82(21):7217-7221.
23. Loveland K.L., McFarlane J.R., et al. Expression of activin beta C subunit mRNA in reproductive tissues. J. Mol. Endocrinol. 1996, 17(1):61-65.
24. Mason A.J., Hayflick J.S., Ling N., Esch F., Ueno N., Ying S.Y., Guillemin R., Niall H., Seeburg P.H. Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-beta. Nature 1985, 318(6047):659-663.
25. Massague J. The TGF-beta family of growth and differentiation factors. Cell 1987, 49(4):437-438.
26. Massague J. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell 1996, 85(7):947-950.
27. Matzuk M.M., Kumar T.R., et al. Functional analysis of activins during mammalian development. Nature 1995, 374(6520):354-356.
28. McCullagh D. Dual endocrine activity of the testis. Science 1932, 76:19-20.
29. McKenzie S., Kyprianou N. Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J. Cell. Biochem. 2006, 97(1):18-32.
30. McPherson S., Thomas T., et al. Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. J. Endocrinol. 1997, 154:535-545.
31. McPherson S.J., Mellor S.L., et al. Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology 1999, 140(11):5303-5309.
32. Mellor S.L., Ball E.M., et al. Activin betaC-subunit heterodimers provide a new mechanism of regulating activin levels in the prostate. Endocrinology 2003, 144(10):4410-4419.
33. Mellor S.L., Cranfield M., et al. Localization of activin beta(A)-, beta(B)-, and beta(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of beta(C)-subunit. J. Clin. Endocrinol. Metab. 2000, 85(12):4851-4858.
34. Mellor S.L., Richards M.G., et al. Loss of the expression and localization of inhibin alpha-subunit in high grade prostate cancer. J. Clin. Endocrinol. Metab. 1998, 83(3):969-975.
35. Onichtchouk D., Chen Y.G., et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 1999, 401(6752):480-485.
36. Risbridger G., Frydenberg M. Endocrinology of Prostate Cancer. Endocrinology 2004, W.B. Sanders, Philadelphia, PA. L.J.D. Groot (Ed.).
37. Risbridger G.P. Activins, Growth factors & Cytokines. Encyclopaedia of hormones 2006, San Diego, Elsevier Press, Academic Press.
38. Risbridger G.P., Ball E.M., et al. Re-evaluation of inhibin alpha subunit as a tumour suppressor in prostate cancer. Mol. Cell. Endocrinol. 2004, 225(1-2):73-76.
39. Risbridger G.P., Frydenberg M., Hayward S.W., Clark P.E., Appu S. Endocrinology of the Prostate. Endocrinology 2009, L.J.D. Groot (Ed.).
40. Risbridger G.P., Schmitt J.F., Robertson D.R. Activins and inhibins and activns in endocrine and other tumours. Endocr. Rev. 2001, 22(6):836-858.
41. Risbridger G.P., Shibata A., et al. Elevated expression of inhibin alpha in prostate cancer. J. Urol. 2004, 171(1):192-196.
42. Robertson D., Klein R., et al. The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochem. Biophys. Res. Commun. 1987, 149:744-749.
43. Schmitt J.F., Millar D.S., et al. Hypermethylation of the inhibin alpha-subunit gene in prostate carcinoma. Mol. Endocrinol. 2002, 16(2):213-220.
44. Schneyer A., Rzucidlo D., et al. Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology 1994, 135:667-674.
45. Schneyer A., Tortoriello D., et al. Follistatin-related protein (FSRP): a new member of the follistatin gene family. Mol. Cell. Endocrinol. 2001, 180(1-2):33-38.
46. Schneyer A.L., Hall H.A., Lambert-Messerlian G., Wang Q.F., Sluss P., Crowley W.F. Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically. Endocrinology 1996, 137(1):240-247.
47. Sharifi N., Lechleider R.J., Farrar William L., et al. Transforming growth factor-b receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?. J. Mol. Endocrinol. 2007, 39:329-332.
48. Takebayashi-Suzuki K., Funami J., et al. Interplay between the tumor suppressor p53 and TGF beta signaling shapes embryonic body axes in Xenopus. Development 2003, 130(17):3929-3939.
49. Thomas T., Wang H., et al. Expression and localisation of activin subunits and follistatins in tissues from men with high grade prostate cancer. J. Clin. Endocrinol. Metab. 1997, 82:3851-3858.
50. Thomas T.Z., Chapman S.M., et al. Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia. Prostate 1998, 34(1):34-43.
51. Tumminello F.M., Badalamenti G., et al. Serum follistatin in patients with prostate cancer metastatic to the bone. Clin. Exp. Metastasis 2010, 27(8):549-555.
52. Ueno N., Ling N., et al. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc. Natl. Acad. Sci. USA 1987, 84(23):8282-8286.
53. Vale W., Rivier J., et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986, 321(6072):776-779.
54. Vale W., Rivier C., Hsueh A., Campen C., Meunier H., Bicsak T., Vaughan J., Corrigan A., Bardin W., Sawchenko P., et al. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog. Horm. Res. 1988, 44:1-34.
55. Yingling J.M., Blanchard K.L., et al. Development of TGF-beta signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 2004, 3(12):1011-1022.